I
The startup develops isoform-specific antibodies that target pathogenic messenger RNA splicing and vascular endothelial growth factor A to enhance blood flow in patients with peripheral arterial disease. This technology provides a treatment option for ischemic diseases where current therapies are limited, facilitating improved vascular health.
Nottingham, United Kingdom
Updated 2 months ago
Funding
$10.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops isoform-specific antibodies that target pathogenic messenger RNA splicing and vascular endothelial growth factor A to enhance blood flow in patients with peripheral arterial disease. This technology provides a treatment option for ischemic diseases where current therapies are limited, facilitating improved vascular health.